GP-101 regulatory update

Genoa said FDA granted Orphan Drug designation to the company’s inhaled GP-101 - an aerosol formulation of pirfenidone - to treat idiopathic pulmonary fibrosis (IPF). The company expects clinical trials of GP-101 to begin early next year. ...